Clinical Trials
Sep 11, 2026 · 1 min read · 22,193 views
More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem
M
Maya Chen
Editorial · Sep 11, 2026
When Jake Van Naarden visits a hospital running clinical trials, he runs into an odd sight. Van Naarden, the head of Eli Lilly's oncology unit, opens a supply closet and sees more than
← Previous
BridgeBio's oncology spinout sticks with SPAC to land on Nasdaq
Next →
Vera eyes full approval for Trutakna in IgAN following positive readout
